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ABSTRACT 19 
Metformin is an anti-diabetic drug with a major impact on regulating blood glucose levels by 20 
decreasing hepatic gluconeogenesis but also affecting other pathways, including glucose 21 
transport and energy/lipid metabolism. Carnivorous fish are considered glucose intolerant, as 22 
they exhibit poor ability to using dietary carbohydrates. To increase the current knowledge 23 
about the molecular mechanisms by which metformin can improve glucose homeostasis in 24 
carnivorous fish, we addressed the effect of intraperitoneal administration of metformin, in 25 
the presence or absence of a glucose load, on metabolic rate-limiting enzymes and lipogenic 26 
factors in the liver of gilthead sea bream (Sparus aurata). Hyperglycemia markedly up-27 
regulated the expression of glycolytic enzymes (glucokinase and 6-phosphofructo-1-kinase, 28 
PFK1) 5 h following glucose administration, while at 24 h post-treatment it increased 29 
isocitrate dehydrogenase (IDH) activity, a key enzyme of the tricarboxylic acid cycle, and the 30 
expression of lipogenic factors (PGC1β, Lpin1 and SREBP1). Metformin counteracted 31 
glucose-dependent effects, and down-regulated glutamate dehydrogenase, alanine 32 
aminotransferase and mTOR 5 h post-treatment in the absence of a glucose load, leading to 33 
decreased long-term activity of PFK1 and IDH. The results of the present study suggest that 34 
hyperglycemia enhances lipogenesis in the liver of S. aurata, and that metformin may exert 35 
specific metabolic effects in fish by decreasing hepatic transdeamination and supressing the 36 
use of amino acids as gluconeogenic substrates. Our findings highlight the role of amino acid 37 
metabolism in the glucose-intolerant carnivorous fish model. 38 
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INTRODUCTION 41 
Metformin (1,1-dimethylbiguanide hydrochloride) is an anti-diabetic drug used for the 42 
treatment of type 2 diabetes to enhance glucose homeostasis by improving the insulin 43 
sensitivity mainly in the liver and skeletal muscle (44). Metformin reduces the hepatic 44 
production of glucose by a mechanism involving inhibition of gluconeogenesis and 45 
glycogenolysis, increased insulin sensitivity and peripheral glucose uptake, and reduced 46 
intestinal glucose absorption (40, 42). Metformin-dependent reduction of hepatic glucose 47 
production involves transitory inhibition of complex I of the mitochondrial respiratory chain, 48 
leading to activation of adenosine monophosphate-activated protein kinase (AMPK), an 49 
energy sensor involved in glucose and lipid metabolism. AMPK activation stimulates 50 
glycolysis while down-regulates the hepatic transcription of gluconeogenic genes (16, 23, 51 
36). In addition, metformin represses lipogenesis and triglycerides accumulation in the liver 52 
through a mechanism that involves induced activation of AMPK and down-regulation of 53 
sterol regulatory element-binding protein (SREBP) 1c, a key transcription factor for de novo 54 
synthesis of lipids (19, 41, 47). Metformin also improves the glucose control via increasing 55 
insulin-stimulated glucose disposal, enhancing insulin receptor tyrosine kinase activity, 56 
increasing glycogen synthesis activity, and enhancing activity of glucose facilitative 57 
transporter type 4 (GLUT4) in skeletal muscle (6). 58 
The molecular action of metformin has been mostly studied in rodents and human-59 
derived cell lines. In fish, metformin reduces blood glucose levels when administrated 60 
intraperitoneally, infused using osmotic pumps or included in the food diet (15, 31, 33, 46). 61 
However, knowledge of mechanisms underlying metformin action in fish remains limited. 62 
Carnivorous fish are considered glucose intolerant mainly due to prolonged hyperglycemia 63 
experienced after a glucose load or intake of high carbohydrate diets (34). The molecular 64 
basis of glucose intolerance in fish has been mainly attributed to dysregulation of enzyme 65 
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activities that control the rate of substrate cycling between glucose and glucose-6-phosphate 66 
in the liver, glucokinase (GK) and glucose-6-phosphatase (G6Pase). In this regard, lower 67 
glucose affinity and postprandial delayed induction of GK expression was reported for 68 
gilthead sea bream (Sparus aurata) (8). In addition, no significant modulation of G6Pase 69 
expression was reported in the liver of rainbow trout (Oncorhynchus mykiss) irrespective of 70 
the carbohydrate content of the diet (29, 30), while insulin hardly affected the promoter 71 
activity of the G6Pase catalytic subunit in the absence of glucose in S. aurata primary 72 
hepatocytes, suggesting that a reduced capacity of insulin-dependent repression of G6Pase 73 
may contribute to insulin resistance in fish (37). 74 
In contrast to observations in mammals, albeit dietary metformin reduced postprandial 75 
glycemia in rainbow trout supplied with high-carbohydrate diets, unexpected induction of 76 
gluconeogenic and lipogenic gene expression by metformin was found in the liver (31). 77 
Indeed, metformin counteracts the effects of insulin after intraperitoneal administration of 78 
glucose in metformin-infused rainbow trout, especially in the muscle, which lead the authors 79 
to conclude that metformin is unable to improve glucose homeostasis under hyperglycemic 80 
conditions in rainbow trout (35). 81 
Considering that the effect of metformin on the intermediary metabolism of carnivorous fish 82 
remains limited to a few species and that the phylogenetic diversity of fish may determine specific 83 
metabolic adaptations, the purpose of the present study was to examine the metabolic effects of 84 
metformin in S. aurata. To this end, we analyzed the effect of intraperitoneal administration of 85 
metformin and glucose on the expression of key enzymes involved in hepatic glycolysis-86 
gluconeogenesis: GK, 6-phosphofructo-1-kinase (PFK1) and fructose-1,6-bisphosphatase (FBPase1). 87 
Given the major role of amino acids as gluconeogenic substrates and fuel in carnivorous fish and the 88 
involvement of metformin on lipogenic gene expression (1, 43, 31), we also studied the effect of 89 
metformin on key enzymes of the tricarboxylic acid cycle (isocitrate dehydrogenase, IDH; and α-90 
ketoglutarate dehydrogenase, OGDH), amino acid metabolism (alanine aminotransferase, ALT; 91 
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aspartate aminotransferase, AST; and glutamate dehydrogenase, GDH), nutrient-sensitive 92 
serine/threonine-protein kinase TOR (mTOR) and lipogenic factors (SREBP1; peroxisome 93 
proliferator-activated receptor gamma coactivator 1-β, PGC1β; and Lpin1). 94 
 95 
MATERIALS AND METHODS 96 
Animals 97 
Gilthead sea bream (S. aurata) juveniles obtained from Piscimar (Burriana, Castellón, Spain) were 98 
maintained at 20 ºC in 260-L aquaria supplied with running seawater as described (13). The diet, 99 
supplied at 30 g/Kg body weight (BW) once a day (10 a.m.), contained 46 % protein, 9.3 % 100 
carbohydrates, 22 % lipids, 10.6 % ash, 12.1 % moisture and 21.1 kJ/g gross energy. To study the 101 
metabolic effects of metformin on S. aurata, four groups of fish were intraperitoneally administered 102 
24 h after the last meal with a volume of 10 μl/g BW containing saline (9 g/L NaCl; control group), 103 
glucose (2 g/Kg BW), metformin (150 mg/Kg BW) and glucose (2 g/Kg BW) + metformin (150 104 
mg/Kg BW), respectively. Five hours and 24 hours following treatment, fish were sacrificed by 105 
cervical section, blood was collected and the liver was dissected out, frozen in liquid N2 and kept at -106 
80 °C until use. To prevent stress, fish were anesthetized with MS-222 (1:12,500) before handling. 107 
The University of Barcelona’s Animal Welfare Committee approved the experimental procedures in 108 
compliance with local and EU legislation. 109 
 110 
Enzyme activity assays and metabolite determinations 111 
In order to obtain liver crude extracts for determination of enzyme activities, powdered frozen 112 
tissue was homogenized (1:5, w/v) in 50 mM Tris–HCl (pH 7.5), 4 mM, EDTA, 50 mM NaF, 0.5 mM 113 
phenylmethylsulfonyl fluoride, 1 mM dithiothreitol and 250 mM sucrose using a PTA-7 Polytron 114 
(Kinematica GmbH, Littau-Luzern, Switzerland) (position 3, 30 s). After centrifugation at 20,000 g 115 
for 30 min at 4 °C, the supernatant was collected and used to perform enzyme activity assays. PFK1 116 
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was assayed after addition of 1 mM ATP to a 200-μl reaction mix containing 100 mM Tris-HCl pH 117 
8.25, 5 mM MgCl2, 50 mM KCl, 0.15 mM ammonium sulfate, 4 mM 2-mercaptoethanol, 0.15 mM 118 
NADH, 10 mM fructose 6-phosphate, 30 mM glucose 6-phosphate, 0.675 U ml-1 aldolase, 5 U ml-1 119 
triose phosphate isomerase, 2 U ml-1 glycerol 3-phosphate dehydrogenase and 4 μl of crude extract. 120 
FBPase1 was monitored in a final volume of 200 μl containing 85 mM imidazole-HCl pH 7.7, 5 mM 121 
MgCl2, 0.5 mM NADP, 12 mM 2-mercaptoethanol, 0.05 mM fructose 1,6-bisphosphate, 2.5 U ml-1 122 
phosphate glucose isomerase, 0.48 U ml-1 glucose 6-phosphate dehydrogenase and 4 μl of extract. 123 
GDH was determined by monitoring NADH oxidation in a 250-μl mixture containing 50 mM 124 
imidazole-HCl (pH 7.4), 250 mM ammonium acetate, 5 mM α-ketoglutaric acid, 0,1 mM NADH, 1 125 
mM ADP and 4 μl crude extract. To assay IDH, NADP+ reduction was assayed after addition of 32 126 
μM NADP+ and 3.9 mM MnSO4 to a final volume of 200 μl containing 80 mM triethanolamine buffer 127 
(pH 7.5), 42 mM NaCl, 3.7 mM isocitrate and 4 μl crude extract. OGDH activity was determined 128 
after addition of 0.12 mM coenzyme A to a final volume of 200 μl containing 50 mM phosphate 129 
buffer (pH 7.4), 2 mM MgCl2, 0.6 mM thiamine pyrophosphate, 2 mM NAD+, 10 mM α-130 
ketoglutarate, 0.2 mM EGTA, 0.4 mM ADP and 4 μl crude extract. ALT and AST were assayed using 131 
commercial kits (Linear Chemicals, Montgat, Barcelona, Spain). All enzyme assays were were 132 
performed at 30 °C and monitored at 340 nm in a Cobas Mira S analyser (Hoffman-La Roche, Basel, 133 
Switzerland). Enzyme activities were expressed per mg of soluble protein (specific activity). One unit 134 
of enzyme activity was defined as the amount of enzyme required to transform 1 μmol of substrate 135 
per min, except for PFK1 activity, which was defined as the amount of enzyme oxidising 2 μmol of 136 
NADH per min. The Bradford method (5) using bovine serum albumin as a standard was adapted for 137 
automated determination of total protein in liver crude extracts as described (27). Serum glucose, 138 
triglycerides and cholesterol were measured with commercial kits (Linear Chemicals, Montgat, 139 
Barcelona, Spain). 140 
 141 
Quantitative real-time RT-PCR 142 
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One μg of total RNA isolated from the liver of S. aurata was reverse-transcribed to cDNA using 143 
Moloney murine leukaemia virus RT (Life technologies, Carsbad, CA, USA) for 1 h at 37 ºC and 144 
random hexamer primers. S. aurata GK, PFK1, FBPase1, GDH, mTOR, SREBP1, PGC1β and Lpin1 145 
mRNA levels were determined in a Step One Plus Real Time PCR System (Applied Biosystems, 146 
Foster City, CA, USA) in a 20-μl mixture containing 0.4 μM of each primer (Table 1), 10 μl of SYBR 147 
Green (Applied Biosystems, Foster City, CA, USA), and 1.6 μl of diluted cDNA. The temperature 148 
cycle protocol for amplification was 95 °C for 10 min, followed by 40 cycles with 95 °C for 15 s and 149 
62 °C for 1 min. A dissociation curve was applied after each experiment to confirm amplification of 150 
one product only. Specificity of the amplification was assayed by amplicon sequencing at least once 151 
for each gene. Standard curves were generated with serial dilutions of control cDNA to determine the 152 
efficiency of PCR reaction for each gene. Amplicon size was checked by agarose gel electrophoresis. 153 
The amount of mRNA for the gene of interest in each sample was normalized with S. aurata 154 
ribosomal subunit 18s, β-actin and elongation factor 1 α (EF1α) as endogenous controls using primer 155 
pairs JDRT18S/JDRT18AS, QBACTINF/QBACTINR and AS-EF1Fw/AS-EF1Rv, respectively 156 
(Table 1). Variations in gene expression were calculated by the standard ΔΔCT method (32). 157 
 158 
Statistics 159 
Analyses were performed with SPSS software Version 24 (IBM, Armonk, NY, USA). Data were 160 
submitted to two-way ANOVA with time (5 h and 24 h) and treatment (saline, glucose, metformin 161 
and glucose + metformin) as independent variables. Student-Newman-Keuls post hoc test was applied 162 
to determine differences among treatments (p < 0.05). 163 
 164 
RESULTS 165 
Five and 24 h following intraperitoneal administration with saline, glucose, metformin, and 166 
glucose plus metformin, serum metabolites and the expression of key enzymes, transcriptional 167 
coactivators and transcription factors involved in the regulation of intermediary metabolism were 168 
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analyzed in the liver of S. aurata. Data on serum glucose, triglycerides and cholesterol are presented 169 
in Figure 1. Plasma glucose levels were significantly affected by sampling time, treatment and their 170 
interaction (Fig. 1A). Five h after glucose injection, plasma glucose levels increased from 3.3 mM in 171 
control animals (saline) to 49.0 mM. Thereafter it decreased to the control values at 24 h post-172 
treatment. At 5 h after the administration of metformin, glycemia reached 7.3 mM (2.2-fold over 173 
control values), while, it promoted a slight hypoglycemia (2.9 mM) 24 h following the treatment. In 174 
combination with glucose, metformin prevented the increase in blood glucose levels: mostly at 5 h 175 
after the treatment and totally at 24 h following the administration (Fig. 1A). No statistical differences 176 
were observed in serum triglycerides and cholesterol concerning the metformin effect. However, both 177 
triglycerides and cholesterol exhibited a similar trend to slightly increase as a result of glucose 178 
administration at 24 h post-treatment. Such effect was totally prevented by the administration of 179 
metformin (Figs. 2B and 2C).  180 
The effect of sampling time and treatment on S. aurata liver mRNA levels for rate-limiting 181 
enzymes in glycolysis-gluconeogenesis is shown in Figure 2. Five h following the treatment, glucose 182 
injection significantly increased mRNA levels and enzyme activity for genes involved in glycolysis 183 
(GK and PFK1), being GK the most affected enzyme. The administration of metformin alone did not 184 
modulate GK expression, while down-regulated PFK1 mRNA levels at 5 and 24 h post-treatment as 185 
well as PFK1 activity at 24 h. When administrated with glucose, metformin totally prevented the 186 
effect of glucose administration on GK and PFK1 expression (Figs. 2A-2D). The mRNA levels of 187 
FBPase1 decreased as a result of metformin administration, while no significant effects were observed 188 
by injecting metformin combined with glucose. At the level of enzyme activity no effects were found 189 
for FBPase1 in any of the treatments performed (Figs. 2E and 2F).  190 
For all treatments, we also analyzed the hepatic activity of two rate-limiting enzymes of the 191 
tricarboxylic acid cycle, IDH and OGDH. Glucose administration significantly increased 2-fold IDH 192 
activity compared to control fish at 24 h after the treatment. The opposite effects were observed after 193 
the administration of metformin alone, while metformin combined with glucose prevented the rise of 194 
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IDH activity promoted by glucose (Fig. 3A). In contrast to IDH, glucose and metformin did not affect 195 
significantly OGDH activity in the liver of S. aurata (Fig. 3B). 196 
The effect of glucose and metformin in regard of key enzyme activities in amino acid metabolism 197 
in the liver is presented in Figure 4. After glucose injection, ALT activity significantly decreased at 24 198 
h compare to control animals. Albeit not significant, a similar trend was observed for AST activity. 199 
Metformin prevented the glucose-dependent decrease in ALT activity 24 h after the treatment (Figs. 200 
4A and 4B). The effect of sampling time and treatment on mRNA levels and enzyme activity of GDH 201 
is shown in Figures 4C and 4D, respectively. Glucose injection did not affect GDH expression at any 202 
of the sampling times studied. However, metformin significantly down-regulated both GDH mRNA 203 
levels (3.3-fold) and activity (2.9-fold) 5 h post-treatment. Twenty-four h after the treatment, GDH 204 
expression was not affected by metformin. 205 
Given that the multiproteic complex mTORC1 is considered a sensor of nutrient availability and 206 
energy status of the cell (18), we analyzed the hepatic mRNA levels of mTOR, a cytosolic 207 
serine/threonine kinase included in the mTORC1 complex. A trend to decrease mTOR expression was 208 
observed 5 h after the administration of metformin. Glucose alone did not affect mTOR expression 209 
and reverted the effect observed with metformin (Fig. 5A). We also addressed the effect of metformin 210 
on transcriptional coactivators and transcription factors involved in the control of lipogenesis. 211 
Experimental treatments significantly affected PGC1β and SREBP1 mRNA levels. Five h following 212 
glucose administration, SREBP1 expression increased 2.7-fold, while at 24 h post-treatment glucose 213 
up-regulated PGC1β and SREBP1 mRNA levels about 2-fold compared to control animals (saline), an 214 
effect that was at least partially reverted when glucose was administered in combination with 215 
metformin. At 5 h after the administration of metformin alone, a tendency to increase PGC1β and 216 
SREBP1 mRNA levels was found (Figs. 5B and 5C). Sampling time also affected Lpin1 expression. 217 
At 5 h post-treatment, metformin up-regulated Lpin1, while glucose in combination with metformin 218 
reverted the effect. At 24 h after the administration, the highest Lpin1 mRNA levels were observed in 219 




Herein we addressed the effect of metformin on key metabolic actors known to play 223 
important roles in the control of postprandial glycemia in the liver of S. aurata. Five h 224 
following glucose administration, blood glucose levels markedly increased and it was totally 225 
recovered 24 h post-treatment. Consistent with previous reports in S. aurata (9, 13, 27), our 226 
findings showed that hyperglycemia led to increased glycolytic rate by stimulating the 227 
expression of GK and PFK1 while hardly affected the activity of the gluconeogenic enzyme, 228 
FBPase1. In the present study, metformin counteracted the activating effect of glucose on GK 229 
and PFK1 expression in the liver of S. aurata. When metformin was administered in the 230 
absence of glucose, it decreased both PFK1 and FBPase1 mRNA levels. However, only a 231 
significant decrease was observed in PFK1 activity 24 h post-treatment, possibly due to 232 
allosteric regulation of both PFK1 and FBPase1 activity. Similarly, the expression of GK, 233 
PFK1, G6Pase, FBPase1 and phosphoenolpyruvate carboxykinase (PEPCK) decreased in the 234 
liver of metformin-infused rainbow trout 6 h following intraperitoneal administration of 235 
glucose (35). However, in the same species, no effect of dietary metformin supplied to fish 236 
fed high carbohydrate diets was observed on the activity of glycolytic enzymes in the liver 237 
and white muscle, while it paradoxically increased the expression of FBPase1 and other 238 
gluconeogenic enzymes (31). Differences in the experimental design as well as metformin 239 
dosage and administration may explain the results obtained in rainbow trout. 240 
Considering rate-limiting enzymes of the tricarboxylic acid cycle (TCA) in the liver of S. 241 
aurata, IDH activity, which catalyzes the oxidative decarboxylation of isocitrate to α-242 
ketoglutarate, appeared to be more sensible than OGDH to experimental treatments: glucose 243 
stimulated IDH activity while metformin decreased the enzyme activity. However, OGDH 244 
activity was not significantly affected. Possibly, increased availability of fuel in the liver after 245 
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glucose administration and glucose-dependent enhancement of glycolysis may be responsible 246 
of long-term enhancement of IDH activity and therefore enable glucose oxidation in the liver 247 
for ATP production. Similarly as in S. aurata, metformin inhibits oxidative reaction of IDH 248 
in human-derived cancer cells (3, 17). 249 
Given that a tendency to increase triglycerides and cholesterol blood levels was observed 250 
24 h following glucose administration, our findings support that hepatic lipogenesis seems an 251 
efficient metabolic pathway for long-term transformation of excess glucose to lipids in S. 252 
aurata. Consistent with this hypothesis, glucose administration up-regulated the expression 253 
of SREBP1, a transcription factor that plays a major role in the transcriptional regulation of 254 
genes involved in fatty acid and cholesterol synthesis (39), and, at long-term, Lpin1 and the 255 
transcriptional coactivator PGC1β, which are also involved in lipogenesis (10, 12). We 256 
previously showed that although S. aurata is a carnivorous fish, it tolerates partial 257 
replacement of dietary protein by carbohydrates through a mechanism that involves 258 
modulation of glycolysis in the liver (8, 13, 25–27). Conceivably, glucose-dependent effects 259 
on SREBP1, Lpin1 and PGC1β mRNA levels, which lasted 24 h after the treatment, may 260 
exert a major role in lipid synthesis from dietary carbohydrates at long-term in the liver.  261 
The administration of metformin prevented glucose-dependent hyperglycemia and the 262 
effects on other serum metabolites, the activity of key enzymes in glycolysis and TCA cycle 263 
as well as in the expression of SREBP1, Lpin1 and PGC1β. In the absence of a glucose load, 264 
a trend to increase SREBP1 and PGC1β mRNA levels was found in the liver of S. aurata 5 h 265 
following the administration of metformin. However, the fact that S. aurata treated with 266 
metformin plus glucose presented lower SREBP1, Lpin1 and PGC1β mRNA levels than 267 
glucose-treated fish, point to down-regulation of hepatic lipogenesis as a result of metformin 268 
action to reduce blood glucose levels in the hyperglycemic state. Metformin-dependent 269 
down-regulation of SREBP1 expression and lipogenesis is consistent with previous 270 
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observations in mammals (19, 28, 41, 47), but contrasts with results reported for rainbow 271 
trout that indicate that dietary metformin increases expression of lipogenic enzymes in the 272 
liver of rainbow trout fed on high-carbohydrate diets (31). Indeed, the administration of 273 
metformin together with insulin up-regulated SREBP1 expression in the liver of rainbow 274 
trout fed high-carbohydrate diets, while metformin alone did not affect SREBP1 mRNA 275 
levels (33). Different metabolic responses to metformin in S. aurata and rainbow trout may 276 
result from the fact that although both species are carnivores, they belong to phylogenetically 277 
distant orders (Spariformes and Salmoniformes, respectively). 278 
Remarkably, at 5 h post-treatment, metformin administration in the absence of a glucose 279 
load down-regulated GDH, which plays a major role in amino acid catabolism by catalyzing 280 
reversible oxidative deamination of L-glutamate into α-ketoglutarate, and ALT activity. 281 
Carnivorous fish exhibit preferential use of amino acids as gluconeogenic substrates and fuel 282 
(1, 43). Indeed, optimal growth of fish requires high levels of dietary protein and amino acids 283 
are the most potent insulin secretagogues in fish (34). Therefore, transdeamination, which 284 
involves transferring of amino groups from amino acids to α-ketoglutarate to produce 285 
glutamate and subsequent glutamate deamination by GDH, is of major importance in fish 286 
liver for entering the carbon skeleton of amino acids into the TCA cycle to obtain energy and 287 
for biosynthetic purposes (7, 14, 20, 22, 38). The fact that metformin markedly decreased 288 
GDH expression and to a lesser extent ALT activity suggests reduced amino acid 289 
deamination and transamination capacity in the liver of S. aurata, and therefore limited use of 290 
amino acid for gluconeogenic purposes, which in turn may be essential for the long-term 291 
hypoglycemic effect of metformin in the liver of S. aurata. In contrast to ALT, AST activity 292 
remained unaffected by metformin. Indeed, although ALT and AST are quantitatively the 293 
most important aminotransferases in the fish liver, previous studies indicated greater 294 
sensibility of ALT to changes in the nutritional status than AST in the liver of S. aurata (2, 295 
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13, 27). In addition to GDH and ALT, metformin down-regulated mTOR expression at 5 h 296 
post-treatment in the liver of S. aurata. Consistently, metformin supplementation suppresses 297 
upregulation of hepatic mTOR mRNA levels when feeding the herbivorous cyprinid 298 
Megalobrama amblycephala with high carbohydrate diets (45). The mTOR pathway is 299 
considered a major signaling pathway in fish and as in mammals is sensitive to the dietary 300 
protein to carbohydrate ratio (4). As in fish, metformin inhibits mTORC1 signaling in 301 
humans (24). Bearing in mind that mTOR is part of the amino acid sensor mTORC1 complex 302 
and that knockdown of GDH1 inhibits mTORC1 activity and leucine requires GDH1 for 303 
promoting mTORC1 activity in human cells (21), our results suggest that metformin may 304 
inhibit mTORC1 signaling by decreasing GDH expression in the liver of S. aurata. 305 
Conceivably, metformin-dependent reduced transdeamination activity in the liver of S. 306 
aurata would decrease availability of amino acid carbon skeletons as fuel and determine the 307 
low levels of PFK1 and IDH activity observed 24 h after metformin administration in the 308 
absence of a glucose load. In this regard, it was proposed that inhibition of mTORC1 309 
improves glucose tolerance by inhibiting hepatic gluconeogenesis in rainbow trout (11). 310 
 311 
PERSPECTIVES AND SIGNIFICANCE 312 
The present study addressed for the first time the effect of acute metformin treatment on 313 
the intermediary metabolism of S. aurata. Our findings suggest that hyperglycemia enhances 314 
lipogenesis in the liver and that metformin may improve glucose homeostasis by 315 
counteracting the activating effects of glucose on the activity of rate-limiting enzymes in 316 
glycolysis and TCA as well as the expression of lipogenic factors. In addition, the present 317 
study provides evidence that metformin may reduce the gluconeogenic rate by decreasing 318 
hepatic transdeamination and the entrance of amino acids into the TCA cycle in fish. Further 319 
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studies are needed to better understand the link between metformin action, GDH expression 320 
and the use of amino acids as gluconeogenic substrates in carnivorous fish. 321 
 322 
ACKNOWLEDGEMENTS 323 
The authors thank Piscimar (Burriana, Castellón, Spain) for providing S. aurata juveniles and 324 
Aquarium of Barcelona (Barcelona, Spain) for supplying filtered seawater. 325 
 326 
GRANTS 327 
This work was supported by the AGL2016-78124-R grant (MEC, Spain; cofunded by the 328 
European Regional Development Fund, EC). 329 
 330 
DISCLOSURES 331 
No conflicts of interest, financial or otherwise, are declared by the authors. 332 
 333 
AUTHOR CONTRIBUTION 334 
I.M., I.V.B. and J.I.S.-M. conceived and designed research; A.R., L.S. and J.I.S.-M. performed 335 
experiments; I.M., J.I.S.-M. and A.R. analyzed data and interpreted results of experiments; A.R. and 336 
I.M. prepared figures and drafted manuscript; A.R., J.I.S.-M., L.S., I.M. and I.V.B. edited and revised 337 
manuscript, and approved final version of manuscript. 338 
 339 
REFERENCES  340 
1.  Andoh T. Amino acids are more important insulinotropins than glucose in a teleost fish, barfin 341 
flounder (Verasper moseri). Gen Comp Endocrinol 151: 308–17, 2007. 342 
2.  Anemaet IG, Metón I, Salgado MC, Fernández F, Baanante IV. A novel alternatively 343 
 15
spliced transcript of cytosolic alanine aminotransferase gene associated with enhanced 344 
gluconeogenesis in liver of Sparus aurata. Int J Biochem Cell Biol 40: 2833–2844, 2008. 345 
3.  Bai M, Yang L, Liao H, Liang X, Xie B, Xiong J, Tao X, Chen X, Cheng Y, Chen X, Feng 346 
Y, Zhang Z, Zheng W. Metformin sensitizes endometrial cancer cells to chemotherapy 347 
through IDH1-induced Nrf2 expression via an epigenetic mechanism. Oncogene ( June 19, 348 
2018). doi: 10.1038/s41388-018-0360-7. 349 
4.  Borges P, Valente LMP, Véron V, Dias K, Panserat S, Médale F. High dietary lipid level is 350 
associated with persistent hyperglycaemia and downregulation of muscle Akt-mTOR pathway 351 
in Senegalese sole (Solea senegalensis). PLoS One 9: e102196, 2014. 352 
5.  Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of 353 
protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254, 1976. 354 
6.  Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, Baron A, Fineman M. 355 
The primary glucose-lowering effect of metformin resides in the gut, not the circulation: 356 
results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care 39: 357 
198–205, 2016. 358 
7.  Caballero-Solares A, Viegas I, Salgado MC, Siles AM, Sáez A, Metón I, Baanante IV, 359 
Fernández F. Diets supplemented with glutamate or glutamine improve protein retention and 360 
modulate gene expression of key enzymes of hepatic metabolism in gilthead seabream (Sparus 361 
aurata) juveniles. Aquaculture 444: 79–87, 2015. 362 
8.  Caseras A, Metón I, Fernández F, Baanante IV. Glucokinase gene expression is 363 
nutritionally regulated in liver of gilthead sea bream (Sparus aurata). Biochim Biophys Acta 364 
1493: 135–141, 2000. 365 
9.  Caseras A, Metón I, Vives C, Egea M, Fernández F, Baanante IV. Nutritional regulation of 366 
glucose-6-phosphatase gene expression in liver of the gilthead sea bream (Sparus aurata). Br J 367 
Nutr 88: 607–614, 2002. 368 
 16
10.  Chen Y, Rui B-B, Tang L-Y, Hu C-M. Lipin family proteins - key regulators in lipid 369 
metabolism. Ann Nutr Metab 66: 10–18, 2015. 370 
11.  Dai W, Panserat S, Terrier F, Seiliez I, Skiba-Cassy S. Acute rapamycin treatment 371 
improved glucose tolerance through inhibition of hepatic gluconeogenesis in rainbow trout 372 
(Oncorhynchus mykiss). Am J Physiol Regul Integr Comp Physiol 307: R1231-8, 2014. 373 
12.  Ducheix S, Vegliante MC, Villani G, Napoli N, Sabbà C, Moschetta A. Is hepatic 374 
lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator 375 
PGC-1β. Cell Mol Life Sci 73: 3809–3822, 2016. 376 
13.  Fernández F, Miquel AG, Cordoba M, Varas M, Metón I, Caseras A, Baanante IV. 377 
Effects of diets with distinct protein-to-carbohydrate ratios on nutrient digestibility, growth 378 
performance, body composition and liver intermediary enzyme activities in gilthead sea bream 379 
(Sparus aurata, L.) fingerlings. J Exp Mar Bio Ecol 343: 1–10, 2007. 380 
14.  Gaspar C, Silva-Marrero JI, Salgado MC, Baanante IV, Metón I. Role of upstream 381 
stimulatory factor 2 in glutamate dehydrogenase gene transcription. J Mol Endocrinol 60: 1–382 
13, 2018. 383 
15.  Hertz Y, Epstein N, Abraham M, Madar Z, Hepher B, Gertler A. Effects of metformin on 384 
plasma insulin, glucose metabolism and protein synthesis in the common carp (Cyprinus 385 
carpio L.). Aquaculture 80: 175–187, 1989. 386 
16.  Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and 387 
diabetes prevention. Drugs 75: 1071–1094, 2015. 388 
17.  Keibler MA, Wasylenko TM, Kelleher JK, Iliopoulos O, Vander Heiden MG, 389 
Stephanopoulos G. Metabolic requirements for cancer cell proliferation. Cancer Metab 4: 16, 390 
2016. 391 
18.  Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 149: 274–392 
 17
293, 2012. 393 
19.  Liu Z-Q, Song X-M, Chen Q-T, Liu T, Teng J-T, Zhou K, Luo D-Q. Effect of metformin 394 
on global gene expression in liver of KKAy mice. Pharmacol Reports 68: 1332–1338, 2016. 395 
20.  Liu Z, Zhou Y, Liu S, Zhong H, Zhang C, Kang X, Liu Y. Characterization and dietary 396 
regulation of glutamate dehydrogenase in different ploidy fishes. Amino Acids 43: 2339–2348, 397 
2012. 398 
21.  Lorin S, Tol MJ, Bauvy C, Strijland A, Poüs C, Verhoeven AJ, Codogno P, Meijer AJ. 399 
Glutamate dehydrogenase contributes to leucine sensing in the regulation of autophagy. 400 
Autophagy 9: 850–860, 2013. 401 
22.  Lushchak VI, Husak V V, Storey KB. Regulation of AMP-deaminase activity from white 402 
muscle of common carp Cyprinus carpio. Comp Biochem Physiol B Biochem Mol Biol 149: 403 
362–369, 2008. 404 
23.  Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-405 
Knudsen M, Gomes AP, Ward TM, Minor RK, Blouin M-J, Schwab M, Pollak M, Zhang 406 
Y, Yu Y, Becker KG, Bohr VA, Ingram DK, Sinclair DA, Wolf NS, Spindler SR, Bernier 407 
M, de Cabo R. Metformin improves healthspan and lifespan in mice. Nat Commun 4: 2192, 408 
2013. 409 
24.  Melnik BC, Schmitz G. Metformin: an inhibitor of mTORC1 signaling. J Endocrinol 410 
Diabetes Obes 2: 1029, 2014. 411 
25.  Metón I, Caseras A, Fernández F, Baanante IV. 6-Phosphofructo-2-kinase/fructose-2,6-412 
bisphosphatase gene expression is regulated by diet composition and ration size in liver of 413 
gilthead sea bream, Sparus aurata. Biochim Biophys Acta 1491: 220–228, 2000. 414 
26.  Metón I, Fernández F, Baanante IV. Short- and long-term effects of refeeding on key 415 
enzyme activities in glycolysis–gluconeogenesis in the liver of gilthead seabream (Sparus 416 
 18
aurata). Aquaculture 225: 99–107, 2003. 417 
27.  Metón I, Mediavilla D, Caseras A, Cantó E, Fernández F, Baanante IV. Effect of diet 418 
composition and ration size on key enzyme activities of glycolysis-gluconeogenesis, the 419 
pentose phosphate pathway and amino acid metabolism in liver of gilthead sea bream (Sparus 420 
aurata). Br J Nutr 82: 223–232, 1999. 421 
28.  de Oliveira Santana KN, Lelis DF, Mendes KL, Lula JF, Paraíso AF, Andrade JMO, 422 
Feltenberger JD, Cota J, da Costa DV, de Paula AMB, Guimarães ALS, Santos SHS. 423 
Metformin reduces lipogenesis markers in obese mice fed a low-carbohydrate and high-fat 424 
diet. Lipids 51: 1375–1384, 2016. 425 
29.  Panserat S, Capilla E, Gutierrez J, Frappart PO, Vachot C, Plagnes-Juan E, Aguirre P, 426 
Brèque J, Kaushik S. Glucokinase is highly induced and glucose-6-phosphatase poorly 427 
repressed in liver of rainbow trout (Oncorhynchus mykiss) by a single meal with glucose. 428 
Comp Biochem Physiol B Biochem Mol Biol 128: 275–283, 2001. 429 
30.  Panserat S, Médale F, Brèque J, Plagnes-Juan E, Kaushik S. Lack of significant long-term 430 
effect of dietary carbohydrates on hepatic glucose-6-phosphatase expression in rainbow trout 431 
(Oncorhynchus mykiss). J Nutr Biochem 11: 22–29, 2000. 432 
31.  Panserat S, Skiba-Cassy S, Seiliez I, Lansard M, Plagnes-Juan E, Vachot C, Aguirre P, 433 
Larroquet L, Chavernac G, Medale F, Corraze G, Kaushik S, Moon TW. Metformin 434 
improves postprandial glucose homeostasis in rainbow trout fed dietary carbohydrates: a link 435 
with the induction of hepatic lipogenic capacities? Am J Physiol Integr Comp Physiol 297: 436 
R707–R715, 2009. 437 
32.  Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. 438 
Nucleic Acids Res 29: e45, 2001. 439 
33.  Polakof S, Moon TW, Aguirre P, Skiba-Cassy S, Panserat S. Glucose homeostasis in 440 
rainbow trout fed a high-carbohydrate diet: metformin and insulin interact in a tissue-441 
 19
dependent manner. Am J Physiol Integr Comp Physiol 300: R166–R174, 2011. 442 
34.  Polakof S, Panserat S, Soengas JL, Moon TW. Glucose metabolism in fish: a review. J 443 
Comp Physiol B 182: 1015–1045, 2012. 444 
35.  Polakof S, Skiba-Cassy S, Panserat S. Glucose homeostasis is impaired by a paradoxical 445 
interaction between metformin and insulin in carnivorous rainbow trout. Am J Physiol Regul 446 
Integr Comp Physiol 297: R1769–R1776, 2009. 447 
36.  Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding 448 
pockets. Biochem J 471: 307–322, 2015. 449 
37.  Salgado MC, Metón I, Egea M, Baanante IV. Transcriptional regulation of glucose-6-450 
phosphatase catalytic subunit promoter by insulin and glucose in the carnivorous fish, Sparus 451 
aurata. J Mol Endocrinol 33: 783–795, 2004. 452 
38.  Sánchez-Muros MJ, García-Rejón L, García-Salguero L, de la Higuera M, Lupiáñez JA. 453 
Long-term nutritional effects on the primary liver and kidney metabolism in rainbow trout. 454 
Adaptive response to starvation and a high-protein, carbohydrate-free diet on glutamate 455 
dehydrogenase and alanine aminotransferase kinetics. Int J Biochem Cell Biol 30: 55–63, 456 
1998. 457 
39.  Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology - divergent 458 
pathophysiology. Nat Rev Endocrinol 13: 710–730, 2017. 459 
40.  van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and 460 
glucose metabolism and possible benefit of combination therapy. Cardiovasc Diabetol 17: 94, 461 
2018. 462 
41.  Tang X, Li J, Xiang W, Cui Y, Xie B, Wang X, Xu Z, Gan L. Metformin increases hepatic 463 
leptin receptor and decreases steatosis in mice. J Endocrinol 230: 227–237, 2016. 464 
42.  Ursini F, Russo E, Pellino G, D’Angelo S, Chiaravalloti A, De Sarro G, Manfredini R, De 465 
 20
Giorgio R. Metformin and autoimmunity: a “new deal” of an old drug. Front Immunol 9: 466 
1236, 2018. 467 
43.  Vilhelmsson OT, Martin SAM, Médale F, Kaushik SJ, Houlihan DF. Dietary plant-protein 468 
substitution affects hepatic metabolism in rainbow trout (Oncorhynchus mykiss). Br J Nutr 92: 469 
71–80, 2004. 470 
44.  Wang Z, Lai S-T, Xie L, Zhao J-D, Ma N-Y, Zhu J, Ren Z-G, Jiang G-L. Metformin is 471 
associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a 472 
systematic review and meta-analysis. Diabetes Res Clin Pract 106: 19–26, 2014. 473 
45.  Xu C, Liu W-B, Zhang D-D, Cao X-F, Shi H-J, Li X-F. Interactions between dietary 474 
carbohydrate and metformin: Implications on energy sensing, insulin signaling pathway, 475 
glycolipid metabolism and glucose tolerance in blunt snout bream Megalobrama 476 
amblycephala. Aquaculture 483: 183–195, 2018. 477 
46.  Zang L, Shimada Y, Nishimura N. Development of a novelzebrafish model for type 2 478 
diabetes mellitus. Sci Rep 7: 1461, 2017. 479 
47.  Zhu X, Yan H, Xia M, Chang X, Xu X, Wang L, Sun X, Lu Y, Bian H, Li X, Gao X. 480 
Metformin attenuates triglyceride accumulation in HepG2 cells through decreasing stearyl-481 
coenzyme A desaturase 1 expression. Lipids Health Dis 17: 114, 2018. 482 
  483 
 21
FIGURE LEGENDS 484 
Fig. 1. Effect of glucose and metformin administration on serum metabolite levels in S. aurata. 485 
Twenty-four h after the last meal, four groups of fish were intraperitoneally administered with saline 486 
(control), 2 g/Kg BW glucose, 150 mg/Kg BW metformin and 2 g/Kg BW glucose + 150 mg/Kg BW 487 
metformin, respectively. Five and 24 h following the treatment, blood was collected and serum 488 
recovered. Serum levels of glucose (A), triglycerides (B) and cholesterol (C) are presented as mean ± 489 
SE (n = 6 fish). Statistical significance for independent variables (sampling time and treatment) are 490 
indicated as follows: *P < 0.05; ***P < 0.001; NS not significant. Homogeneous subsets for the 491 
treatment are shown with different letters (P < 0.05). 492 
 493 
Fig. 2. Effect of glucose and metformin administration on the expression of key enzymes in 494 
glycolysis-gluconeogenesis in the liver of S. aurata. Twenty-four h after the last meal, four groups of 495 
fish were intraperitoneally administered with saline (control), 2 g/Kg BW glucose, 150 mg/Kg BW 496 
metformin and 2 g/Kg BW glucose + 150 mg/Kg BW metformin, respectively. Five and 24 h 497 
following the treatment, the liver was collected and RNA isolated. Hepatic mRNA levels and enzyme 498 
activity of GK (A, B), PFK1 (C, D) and FBPase1 (E, F) are presented as mean ± SE (n = 6 fish). 499 
Expression levels for each gene were normalized using ribosomal subunit 18s, β-actin and EF1α as 500 
housekeeping genes. Statistical significance for independent variables (sampling time and treatment) 501 
are indicated as follows: *P < 0.05; **P < 0.01; ***P < 0.001; NS not significant. Homogeneous 502 
subsets for the treatment are shown with different letters (P < 0.05). 503 
 504 
Fig. 3. Effect of glucose and metformin administration on the activity of key enzymes in the 505 
tricarboxylic acid cycle in the liver of S. aurata. Twenty-four h after the last meal, four groups of fish 506 
were intraperitoneally administered with saline (control), 2 g/Kg BW glucose, 150 mg/Kg BW 507 
metformin and 2 g/Kg BW glucose + 150 mg/Kg BW metformin, respectively. Five and 24 h 508 
following the treatment, the liver was collected. Enzyme activity levels of IDH (A) and OGDH (B) 509 
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are presented as mean ± SE (n = 6 fish). Statistical significance for independent variables (sampling 510 
time and treatment) are indicated as follows: *P < 0.05; **P < 0.01; NS not significant. Homogeneous 511 
subsets for the treatment are shown with different letters (P < 0.05). 512 
 513 
Fig. 4. Effect of glucose and metformin administration on key enzymes in amino acid metabolism in 514 
the liver of S. aurata. Twenty-four h after the last meal, four groups of fish were intraperitoneally 515 
administered with saline (control), 2 g/Kg BW glucose, 150 mg/Kg BW metformin and 2 g/Kg BW 516 
glucose + 150 mg/Kg BW metformin, respectively. Five and 24 h following the treatment, the liver 517 
was collected and RNA isolated. Enzyme activity values of ALT (A), AST (B) and mRNA levels as 518 
well as enzyme activity of GDH (C, D) are presented as mean ± SE (n = 6 fish). Expression levels for 519 
GDH were normalized using ribosomal subunit 18s, β-actin and EF1α as housekeeping genes. 520 
Statistical significance for independent variables (sampling time and treatment) are indicated as 521 
follows: *P < 0.05; **P < 0.01; ***P < 0.001; NS not significant. Homogeneous subsets for the 522 
treatment are shown with different letters (P < 0.05). 523 
 524 
Fig. 5. Effect of glucose and signalling metformin administration on the mRNA levels of signalling 525 
proteins involved in the control of intermediary metabolism in the liver of S. aurata. Twenty-four h 526 
after the last meal, four groups of fish were intraperitoneally administered with saline (control), 2 527 
g/Kg BW glucose, 150 mg/Kg BW metformin and 2 g/Kg BW glucose + 150 mg/Kg BW metformin, 528 
respectively. Five and 24 h following the treatment, the liver was collected and RNA isolated. The 529 
mRNA levels of mTOR (A), PGC1β (B), SREBP1 (C) and Lpin1 (D) are presented as mean ± SE (n 530 
= 6 fish). Expression levels for each gene were normalized using ribosomal subunit 18s, β-actin and 531 
EF1α as housekeeping genes. Statistical significance for independent variables (sampling time and 532 
treatment) are indicated as follows: *P < 0.05; **P < 0.01; ***P < 0.001; NS not significant. 533 
Homogeneous subsets for the treatment are shown with different letters (P < 0.05).  534 
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Table 1. Oligonucleotides used in the present study. 535 
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